![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Article |
|---|---|
| Title: | A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2 |
| Creators Name: | Mansour, A.M., Drevs, J., Esser, N., Hamada, F.M., Badary, O.A., Unger, C., Fichtner, I. and Kratz, F. |
| Abstract: | The progression of malignant melanoma is characterized by overexpression of a number of matrix metalloproteinases (MMPs), especially MMP-2, which play a critical role in the degradation of basement membranes and the extracellular matrix. Consequently, we assessed a drug targeting strategy in which the protease activity of MMP-2 is exploited to release an anticancer agent from a macromolecular carrier, i.e., circulating albumin. For this purpose, a water-soluble maleimide derivative of doxorubicin (1) incorporating a MMP-2 specific peptide sequence (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) was developed that binds rapidly and selectively to the cysteine-34 position of circulating albumin. The albumin-bound form of 1 was efficiently and specifically cleaved by MMP-2 liberating a doxorubicin tetrapeptide (Ile-Ala-Gly-Gln-DOXO) and subsequently doxorubicin. In vivo, 1 was superior to the parent compound doxorubicin in the A375 human melanoma xenograft, which is characterized by a high expression of MMP-2. |
| Keywords: | Albumins, Antineoplastic Antibiotics, Cultured Tumor Cells, Doxorubicin, Maleimides, Matrix Metalloproteinase 2, Melanoma, Oligopeptides, Prodrugs |
| Source: | Cancer Research |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Volume: | 63 |
| Number: | 14 |
| Page Range: | 4062-4066 |
| Date: | 15 July 2003 |
| Official Publication: | http://cancerres.aacrjournals.org/cgi/content/abstract/63/14/4062 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
